BELLEVUE, Wash., April 17, 2018 -- Voip-Pal.com Inc. (“Voip-Pal”, “Company”) (OTCQB:VPLM) is pleased to announce that it was issued U.S. Patent No. 9,948,549 today.
Following today’s issuance, Voip-Pal now owns seventeen issued U.S. patents and three allowed U.S. patent applications.
The Company’s litigation against Apple and several other companies has asserted only two patents—namely, U.S. Patent Nos. 8,542,815 and 9,179,005 (also referred to as the ‘815 and ‘005 patents). On November 20, 2017, the Patent Trial and Appeals Board (PTAB) issued their Final Written Decisions, upholding the validity of the ‘815 and ‘005 patents, which had been challenged by Apple in their inter partes review (IPR) petitions. Apple subsequently filed post-judgment motions in the IPR proceedings seeking invalidation of the ‘815 and ‘005 patents or a new trial in the alternative, as a sanction against Voip-Pal.
Emil Malak, CEO of Voip-Pal stated, “We are still awaiting the PTAB’s decision on this matter. It is our firm belief that Apple’s sanctions request will be denied as meritless, after which Voip-Pal can resume its patent lawsuits.”
For more information on Voip-Pal’s patents please visit www.voip-pal.com/patents-detail
About Voip-Pal.com Inc.
Voip-Pal.Com, Inc. (“Voip-Pal”) is a publicly traded corporation (OTCQB:VPLM) headquartered in Bellevue, Washington. The Company owns a portfolio of patents relating to Voice-over-Internet Protocol (“VoIP”) technology that it is currently looking to monetize.
Any forecast of future financial performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Corporate Website: www.voip-pal.com
IR inquiries: [email protected]
IR Contact: Rich Inza (954) 495-4600


Meta, U.S. States Discuss Settlement in Teen Addiction Trial
Trump Administration Plans New Drug Pricing Deals With Biotech Firms
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat
PayPal Shares Sink as $50 Billion Takeover Bid Collapses
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’
Amazon Secures 200 MW Wind Power Deals in Sweden
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition
OpenAI AI Agent Swarm Behind Hugging Face Hack
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China
Mercer International Stock Surges 45% on C$20 Million Canada Funding
Google Expands Gemini Enterprise With AI Tools for Legal Sector
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake
Toyota Global Sales Fall as China Demand Slumps 



